CH
抗体药类似物
Research Grade Bimekizumab
All
  • CatalogTD-HS856036
  • ClonalitymAb
  • Application Research Grade Biosimilar
  • SynonymsCDP4940, UCB-4940, UCB4940, CAS: 1418205-77-2
  • Specification
    1mg
  • Prices
    ¥询价
Customized service consulting

Research Grade Bimekizumab


Catalog No. TD-HS856036
Species reactivity Human
Applications Research Grade Biosimilar
Host species Humanized
Isotype IgG1-kappa
Expression system Mammalian Cells
Species Human
Clonality Monoclonal
Target CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A, IL17F, Interleukin-17F, IL-17F, Cytokine ML-1
Endotoxin level Please contact with the lab for this information.
Purity >95% as determined by SDS-PAGE.
Purification Protein A/G purified from cell culture supernatant.
Accession Q16552 & Q96PD4
Form Liquid
Storage buffer 0.01M PBS, pH 7.4.
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternate Names CDP4940, UCB-4940, UCB4940, CAS: 1418205-77-2
Background Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation.
Note For research use only. Not suitable for clinical or therapeutic use.